CMV-alphaDC1 vaccine
/ Roswell Park
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 06, 2023
A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
(clinicaltrials.gov)
- P1b | N=0 | Withdrawn | Sponsor: Roswell Park Cancer Institute | N=12 ➔ 0 | Not yet recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Disorders • Hematological Malignancies • Infectious Disease • Oncology • Transplantation • IFNG
1 to 1
Of
1
Go to page
1